FGFR2 and urothelial carcinoma: Erdafitinib, a tyrosine kinase inhibitor (TKI) of FGFR, was approved by the USA FDA in April 2019 for advanced urothelial carcinoma with actionable FGFR2/FGFR3 alterations as the first molecularly targeted therapy [14, 15].